International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment

Irvine, California and Amsterdam (ots/PRNewswire) -

Panel's Recommendations Reinforce Clinical Value of Tests
Such

as BluePrint(R)

Agendia, a commercial-stage molecular cancer diagnostics company,
today announced that the 12th St. Gallen International Breast Cancer
Conference (2011) Expert Panel's recommendations highlight the value
of molecular subtyping - classifying patients by the particular
biological subtype of their tumor - in guiding treatment decisions
for breast cancer patients. According to the panel, "it is no longer
tenable to consider breast cancer as a single disease" and clinicians
"should consider cases within the various distinct subtypes in order
to properly assess the relevant evidence and arrive at appropriate
therapeutic advice." The panel's updated guidelines, which are
released on a semiannual basis, appear in the August 2011 issue of
Annals of Oncology in an article titled "Expert Consensus on the
Primary Therapy of Early Breast Cancer 2011" by Goldhirsch, et al
(Annals of Oncology 22: 1736-1747, 2011).

The panel's recommendations support the clinical value of
Agendia's BluePrint assay, which, in combination with the company's
FDA-cleared MammaPrint(R) recurrence test, can accurately classify
all patients as Basal, Luminal-A, Luminal-B, or ERBB2 (HER2) and help
determine appropriate treatment. Both clinically available,
MammaPrint and BluePrint are two components of Agendia's Symphony(TM)
suite of breast cancer treatment products, a comprehensive collection
of genetic assays that help address complex treatment decisions for
any type and stage of breast cancer.

The panel also recognized that MammaPrint provided such accurate
prognoses that patients and physicians may decide that chemotherapy
is not required. MammaPrint identifies patients' risk of metastasis,
placing them into one of just two groups, high risk and low risk.
Women in the low risk group are able to be treated effectively and
safely without undergoing chemotherapy and its side effects.

"These recommendations reinforce what Agendia has known for some
time - that molecular subtyping is an invaluable component of the
treatment decision process in breast cancer," said Dr. Bernhard Sixt,
CEO and Cofounder of Agendia. "Along with MammaPrint's proven
prognostic ability to classify breast cancer patients according to
recurrence risk, BluePrint and Symphony's other tests offer a very
powerful set of tools to help physicians eliminate uncertainty and
make better treatment decisions."

About Agendia:

Agendia [http://www.agendia.com ] is a leading global commercial
molecular diagnostic company that develops and markets genomic-based
diagnostic products that improve the quality of life for cancer
patients and simplifies complex treatment decisions for their
physicians. Agendia's Symphony(TM) suite of breast cancer products is
based on the analysis of hundreds of genes in a patient's breast and
provides unprecedented biological insight to address complex
treatment decisions. Symphony(TM) includes MammaPrint(R), the first
and only FDA-cleared IVDMIA breast cancer recurrence assay, as well
as BluePrint(R), a molecular subtyping assay, TargetPrint(R), an
ER/PR/HER2 expression assay, and TheraPrint(R), a therapy selection
assay. Together, these tests help physicians determine a patient's
individual risk for metastasis, which patients will benefit from
chemo or hormonal therapy, and which patients do not require these
treatments and can instead be treated with other less arduous and
costly methods.

In addition to the Symphony(TM) suite of tests, Agendia has a
rich pipeline of genomic products in development based on its
world-class genomic platform. The company also collaborates with
pharmaceutical companies to develop companion diagnostic tests in the
area of oncology and is a critical partner in the ISPY-2 and MINDACT
trials.

Agendia was founded in 2003 as a spin-off of the Netherlands
Cancer Institute and is based in Irvine, California, United States,
and Amsterdam, the Netherlands. For more information, please visit
http://www.agendia.com.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information, please contact: Ricochet PublicRelations,
Valerie Carter, Tel: +1-202-316-0143, E-mail:vcarter@ricochetpr.com